Defining the Immune-Metabolic Landscape of Aged Allografts: Insights from Metabolomic Profiling in Acute Heart Transplant Rejection
Authors
Affiliations
Abstract
Introduction: Donor age critically influences graft immunogenicity and transplant outcomes, driving organ quality and alloimmune activation. Metabolomics offers a unique means to investigate age-specific immune-metabolic dynamics impacting allograft outcomes. Here, we performed a detailed metabolomic analysis to delineate the augmented immunogenicity of older organs and identify potential age-specific targeted therapies.
Methods: A fully-mismatched heterotopic heart transplant model was used, with donor hearts from young (3-month) and aged (18-month) C57Bl/6 mice, transplanted into young Balb/c recipients. Allografts were collected on day 5 post-transplant, corresponding to peak alloimmunity. Native hearts of non-transplanted young and old C57Bl/6 mice served as controls. CD11b+ myeloid cells and cardiac interstitial fluid (IF) were isolated for LC-MS/MS-based untargeted metabolomic profiling, followed by pathways analysis and validation of differentially-expressed metabolites with targeted metabolomics. Glucosamine—identified as a key metabolite of interest—was further tested in graft survival experiments using our established cardiac transplant model. Recipients received glucosamine (600mg/kg) or PBS (control) starting 1 day preoperatively, then daily thereafter until rejection.
Results: Untargeted metabolomic analysis detected >900 unique metabolites, with 13 compounds consistently altered in both CD11b+ and cardiac IF profiles—suggesting heart-associated immune cell specificity—and further validated with targeted metabolomics. Glucosamine and licochalcone A stood out with prominently reduced concentrations in old allografts. Pathways analysis revealed significantly altered amino acid metabolism, with notable changes in the amino sugar and nucleotide sugar metabolism pathways, thereby further implicating glucosamine as a potential driver of age-dependent immune-metabolic differences. In a model with strong histo-incompatibility and absent immunosuppression, glucosamine administration demonstrated prolonged graft survival in recipients of aged donor grafts, whereas no difference was seen in recipients of young donor hearts. These data suggest that targeting selected metabolites has the potential for individualized and age-specific immunosuppression.
Conclusion: This study highlights the utility of metabolomics in defining age-related immune-metabolic signatures in transplantation, with glucosamine emerging as a promising candidate for targeted therapeutics when transplanting older organs. These findings underscore metabolomics as a platform for biomarker discovery and therapeutic innovation.